Stock info Exelixis Inc | Filter  Basic-Info

Exelixis Inc

The past year was a good year for Exelixis Inc investors

The stock gained over the past 12 months at around 247 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 302 percent. Exelixis Inc's revenues between 2011 and 2015 were quite similar and moved between 47,45 million dollars and 37,17 million dollars. Exelixis Inc's net results between 2011 and 2015 were far from constant and moved between 75,7 million dollars and -169,74 million dollars.

Exelixis Inc primarily operates in the biotech sector. The global biotech companies gained over the past 10 years on average 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Exelixis Inc didn't pay out any dividends (in the past 5 years).

Exelixis Inc financed with a quite low debt position

Last year the balance sheet of the American company was worth 332,34 million dollars. Of the total balance sheet 436,64 million dollars (131,38 percent) was financed by debt. At the end of 2016 the American company was traded with a price/earnings-ratio of around -2. So investors paid -2 times the company's 2015's EPS. Many analysts say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 1,14 billion dollars. At the end of 2015 the American company had around 209,23 million stocks listed.

All Exelixis Inc's annual reports can be found here. More information about Exelixis Inc can be found it's website. .